Thank you and welcome, everyone to our Q2 report here at Medivir AB. James. And, uh, as James said, ASCO and ESMO-GI have taken place this spring and summer. In the second-line setting, where we are developing Fostrox and Lenvatinib, the data has been scarce but consistent with what has been shown previously. And it confirms that Fostrox plus Lenvatinib is a promising second-line treatment in advanced HCC.
And, um, there is a significant gap in clinical data for second-line advanced HCC. And that is really the reason why there is no consensus on what treatment to use.
And the recommendation, as you can see from this ESMO-GI presentation, is still to include these patients in a clinical study.
Not all patients will have a clinical study available. And then you use more or less what is available or what has data in first-line or has been used after Sorafenib.
Um, and also what is again confirmed is that immune therapy is established in first-line and will remain in this setting with, uh, TECENTRIQ Avastin or, as it will say in all these slides, atezolizumab plus bevacizumab, particularly in first-line, which is used in around 90% of the patients in first-line.
You can go to the next slide. So this sounds a little bit crazy actually at a conference that is focusing on liver cancer.
But at ESMO-GI, there was only one presentation with prospective clinical data in the second-line HCC setting.
And this presentation used Cabozantinib in the second line. And it's not only after I, you can see it to the left here, but it was mainly, uh, TECENTRIQ Avastin atezo that was used in the first line setting. And in this study, there was a median progression-free survival of three months and an overall response rate of. It was only one patient that responded, with a response rate of 4.5%. And this is really in line with what we have seen previously.
I can show you some more data if we go to the next slide.
And that was from a prospective registry from Europe, a study that looked into 230 patients who had received either Sorafenib or Lenvatinib in the second-line setting, trying to understand what is the outcome in the second-line setting. So, this is more or less what was presented at ESMO-GI. When it comes to the setting where we are developing Fostrox plus Lenvatinib.
And if you go to the next slide, there has also been a recent review published in Annals of Hepatology in February this year, where they looked into the data in the second-line setting.
And it includes both prospective and retrospective studies here. But all in all, you can say that all of this data confirms what we have seen previously, with an overall response rate of less than 10%, a disease control rate of around 65%, and a median progression-free survival or time to progression of around four months.
And this data can be compared to what we have shown in the Phase 1B/2A study with Fostrox plus Lenvatinib, where we saw an overall response rate of 24%, disease control rate of 81%, and a time to progression of 10.9 months, which is substantially better than what has been seen with Lenvatinib, with other TKIs, or with immunotherapy combinations in the same setting in second-line advanced HCC.
Uh, and with this limited clinical data in second line, the development in HCC is really focused on first line liver cancer.
There is, however, continued support for immune therapy. In the first-line setting.
It's solid, and it's further supported by quality of life, an endpoint that has not been so much in focus in oncology development. But recently, ESMO-GI and similar conferences have started to recognize health-related quality of life as a key parameter in determining the clinical value of anti-cancer treatments. And it could also enhance the overall assessment of therapeutic efficacy. And why am I saying this here now? It's because the current treatment algorithm is the one that we are working with. And if you go to the next slide, we can also see a recent publication in support of immune therapy in first-line, where they integrated health-related quality of life in addition to overall survival.
The most important endpoint in liver cancer shows that TECENTRIQ Avastin or Bev outperformed all other treatments and provided the best balance between quality of life preservation.
Uh, that quality of life didn't deteriorate, uh, along with overall survival in advanced HCC. So, our firm assumption is that TECENTRIQ Avastin will continue to be the preferred first-line treatment option, also in the future.
And our planned phase two study post-immunotherapy will reflect the future treatment algorithm.
And the results from our study will be relevant for the high unmet need in the second-line setting.
And with that, I will leave it back to Jess.